Embeda

This forum made possible through the generous support of SDN members, donors, and sponsors. Thank you.

ampaphb

Interventional Spine
15+ Year Member
Joined
May 13, 2007
Messages
4,352
Reaction score
738
Points
5,191
Location
New Orleans, LA
  1. Attending Physician
Recalled Narcotic Analgesic Returning to Market
Pfizer announced that the FDA has approved a Prior Approval Supplement for Embeda (morphine sulfate and naltrexone HCl) Extended-Release Capsules.

Embeda is a Schedule II narcotic indicated for the management of moderate-to-severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

RELATED: Pain Management Resource Center

Embeda was voluntarily recalled in March 2011 because it did not meet a prespecified stability requirement during routine testing. The Prior Approval Supplement included an update to the Embeda manufacturing process that addressed the pre-specified stability requirement.

Embeda extended-release capsules will be available in 20mg/0.8mg and 30mg/1.2mg as 75-count bottles; 50mg/2mg as 150-count bottles; 60mg/2.4mg and 80mg/3.2mg as 200-count bottles; and 100mg/4mg as 300-count bottles. Pfizer anticipates it will be available in the second quarter of 2014.

For more information call (800) 438-1985 or visit Embeda.com.
 
Top Bottom